Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin for latent tuberculosis infection in household contacts of multidrug-resistant tuberculosis patients in Vietnam
ACTRN12616000215426Phase 3Completed
- Sponsor
- University of Sydney
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in latent tuberculosis infection (LTBI), Tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) comparing Levofloxacin with Placebo (2 arms). Primary endpoint: Incidence ratio of bacteriologically confirmed tuberculosis. Started Mar 2016; status: completed.
02
Drugs
levofloxacin
03
Conditions
latent tuberculosis infection (LTBI)Tuberculosis (TB)multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on ACTRN12616000215426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000215426.